Latest Publication 

240. A total of 2,257 patients enrolled in Trials VIII and IX with centrally-assessed ER, PgR, and HER2 were categorized into three IHC defined tumor subtypes: triple negative, HER2 positive and endocrine receptor absent, and endocrine receptor present. Within subgroups defined by tumor subtype, patients randomized to CMF chemotherapy were compared to those who received no chemotherapy. A statistically significantly greater benefit for chemotherapy compared with no chemotherapy was observed in triple negative breast cancer (HR 0.46, 95% CI 0.29–0.73, interaction p=0.009 vs. endocrine receptor-present disease). The magnitude of the chemotherapy effect was lower in HER2-positive endocrine receptor-absent disease (HR 0.58, 95% CI 0.29–1.17, interaction p =0.24 vs. endocrine receptor-present disease). We concluded that the magnitude of benefit of CMF chemotherapy is largest in patients with triple-negative node-negative breast cancer.

Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA. Classical Cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28:2966-2973, 2010. (Trials VIII-IX) (Journal impact factor 17.2).